Novartis India Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- ✓Attractively valued vs sector (P/E 38.8x vs industry 54.4x)
- ✓Virtually debt-free
Concerns
- ✗Trading near 52-week high (₹1,589)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
NOVARTIND · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% |
| FII | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% |
| DII | 0.52% | 0.52% | 0.52% | 0.52% | 0.53% | 0.53% |
| Public | 28.60% | 28.61% | 28.60% | 28.61% | 28.60% | 28.61% |
Latest News
All news →Novartis India reports lower net profit, plans stake sale.
*Novartis India reports lower net profit, plans stake sale.* Q4 and FY26 earnings showed a decline in net profit, missing analyst expectations. The company announced a **stake sale to a consortium**, signaling strategic restructuring. Deal size and terms remain undisclosed. 📊 *STOCKS:* NOVARTISIND | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings
Alembic Pharma gets USFDA tentative nod for Binimetinib tablets
*Alembic Pharma gets USFDA tentative nod for Binimetinib tablets* — Alembic Pharmaceuticals has received tentative approval from the USFDA for its Binimetinib Tablets, 45 mg. The drug is a generic version of Novartis’ Mektovi tablets, used for treating melanoma. Tentative approval means the product can launch upon patent expiry or final regulatory clearance. This positions Alembic to enter the US market early and gain revenue momentum. 📊 *STOCKS:* APLLTD | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA
ChrysCapital's open offer for Novartis India fails due to share surge
*ChrysCapital's open offer for Novartis India fails as shares surge* — ChrysCapital’s open offer to acquire shares in Novartis India failed as the stock price surged past the offer price of **₹7,425 per share**, preventing successful acquisition. The arbitrage window closed due to strong retail interest and market momentum. Only **0.04%** of shares were tendered against the targeted 26%. 📊 *STOCKS:* NOVARTIS | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #M&A
Novartis India open offer gets low public response
*Novartis India open offer sees minimal public share acceptance.* Only **0.36%** of public shares were tendered, far below expectations. The open offer, aimed at increasing stake, saw strong resistance from minority shareholders. Majority shareholding remains unchanged post-offer. 📊 *STOCKS:* NOVARTISIND | 🏢 *SECTOR:* Pharma | #LOWIMPACT #openoffer
Novartis India reports capital expenditure per share metrics
*Novartis India Limited discloses capital expenditure per share metrics on TradingView platform.* This routine fundamental data release provides shareholders with CapEx efficiency insights. The metric helps assess the company's **investment intensity** relative to share count. No major operational changes indicated. 📊 *STOCKS:* $NOVARTIND | 🏢 *SECTOR:* Pharma | #LOWIMPACT #capex